Abstract
Background We conducted a first-in-Japanese, phase I study of ontuxizumab, a humanized, anti-endosialin monoclonal antibody, to confirm its tolerabili......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
